Recently stock market analysts have updated their consensus ratings on shares of Bio-Path Holdings (BPTH). The latest broker reports which are currently outstanding on Monday 9th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

04/18/2016 – Rodman & Renshaw began new coverage on Bio-Path Holdings giving the company a “buy” rating. They now have a USD 5 price target on the stock.

10/14/2015 – Bio-Path Holdings had its “buy” rating reiterated by analysts at Maxim Group. They now have a USD 5 price target on the stock.

01/23/2014 – Bio-Path Holdings had its “outperform” rating reiterated by analysts at Zacks. They now have a USD 7 price target on the stock.

Bio-Path Holdings has a 50 day moving average of 2.55 and a 200 day moving average of 1.78. The stock’s market capitalization is 238.77M, it has a 52-week low of 0.99 and a 52-week high of 3.19.

The share price of the company (BPTH) was up +0.76% during the last trading session, with a high of 2.67 and the volume of Bio-Path Holdings shares traded was 161856.

View other investors thoughts on Bio-Path Holdings on our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.